Genome Editing Market Size is Predicted to Reach $23 Billion by 2030g, growing at a CAGR of 19.2 % during the forecast Period 2023-2030 according to the latest market research report published by IndustryARC. The streaming demand for synthetic genes and personalised medicine and increase in the infectious diseases like Cancer are poised to propel the market growth, finds IndustryARC in its recent report, titled “Genome Editing Market Size, Share & Trends Analysis [By Product and Service Type (reagents and consumables, software and systems, services) By Technology (Restriction Enzymes, Zinc-Finger Nucleases (ZFN), transcription activator-like effector nucleases (TALEN), Clustered regularly interspaced short palindromic repeats (CRISPR), Antisense and Others) By Application(Animal Genetic Engineering, Plant Genetic Engineering, Drug Discovery and Development, Diagnostic applications, Cell Line Engineering, Others) By End User(biotech and pharma companies, Government and Academic Research Institutes, contract research organizations) By Delivery Method( Ex- vivo, In- vivo) By Mode( Contract, In- house) By Geography – Global Opportunity Analysis & Industry Forecast, 2023-2030].
Request Sample Research Report:
North America Contributes with Largest Market Share:
North America Genome Editing Market held the largest share in 2022 contributing with more than 40% of the total market revenue. It is mainly owing to its use in various end varieties of crops to modify the crops to yield better results. Additionally, the region’s predominant position in local infrastructure pertaining to giant bio-pharma companies. The leading genome editing companies in the region are also focussed on continuously conducting experiments in introducing new drugs for various life threating genetic disorders including Hereditary angioedema. In March 2023, INTELLIA Therapeutics, Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s investigational new drug application TLA-2002 for the treatment of hereditary angioedema (HAE), . This will help the company to include the United States in the global Phase 2 portion of its ongoing Phase 1/2 study.
Genome Editing Market 2023-2030: Segmentation
By Product and Service Type
Reagents and Consumables
Software and Systems
Zinc-Finger Nucleases (ZFN)
Transcription activator-like effector nucleases (TALEN)
Clustered regularly interspaced short palindromic repeats (CRISPR)
By Delivery Method
Animal Genetic Engineering
Plant Genetic Engineering
Drug Discovery and Development
Cell Line Engineering
Biotech and Pharma Companies
Government and Academic Research Institutes
Contract Research Organizations (CRO’s)
North America (U.S., Canada and Mexico and Rest of North America)
Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),
Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),
LAMEA (Saudi Arab, Brazil, Qatar, Argentina, South Africa, Nigeria, UAE and Rest of LAMEA)
Rest of the World (Middle East and Africa).
By companies profiled
Thermo Fisher Scientific,Inc.
Integrated DNA Technologies, Inc.
New England Biolabs, Inc.
Sangamo Biosciences, Inc.
Agilent Technologies, Inc.
Horizon Discovery Ltd.
Tecan Genomics, Inc.
Bean Therapeutics, Inc
Bluebird Bio, Inc.
Get Access to Full Research Report:
Genome Editing Market Report – Key Takeaways:
CRISPR Technology is Leading the Market, TALEN is Fastest Growing
CRISPR and CRISPER-Cas9 is an immune defense system to edit the DNA and has redefined the approach to gene therapy across the globe owing to their simplicity and being a more efficient alternative to specific gene editing. This technology is the largest revenue contributor in the genome editing market and is estimated to grow with a double digit CAGR during the forecast period 2023-2030. On the other hand, TALEN technology is witnessed to be growing at the fastest CAGR of 20.3% during the period under study. The major factors behind the fastest growth of TALEN technique is its specificity, versatility and accessibility. It can be used to edit a wide range of organisms including bacteria and plants and can be used for any type of DNA mutation such as substitutions, insertions and deletions.
Asia Pacific Region Grows Fastest, Development of Gene-editing Policies in Many Countries
Asia Pacific market for genome editing is growing fastest during the forecast period 2023-2030. Many regional countries such as Japan, India, Philippines, Vietnam, Indonesia are setting, revising or are coming up with clear guidelines for the use of genome editing tools. Japan has commercialized the gene-edited products and has implemented clear guidelines whereas, in India, Department of Biotechnology has introduced a new set of guidelines for genome editing in 2022, to ensure the safety of environment and organisms under its Environment Protection Act.
Purchase this Premium Report:
Key Opportunity Analysis:
Reduction in Breeding Time through Gene-editing offers Large Opportunities in Agriculture Sector
Gene editing leads to reduced breeding time in the produce any new variety of plants and also reduce the expenses for research and development. This technique offers an opportunity to address a range of difficulties associated with developing durable resistances to ailments, pests and abiotic stresses It also has the potential to reduce costs of crop protection and decrease labour demand. Regulators of different counties have been involved in considering the process to manage gene-edited products in agrifood systems over a decade. For example, in 2022, Health Canada published a scientific opinion on the regulation of gene-edited plant products which stated that novel food products from any breeding technique that might represent a food safety hazard would require a food safety assessment, to be done according to domestic guidance.
Gene-editing Increasingly Gaining Momentum in Europe, Seeking Relaxation of Rules
Countries such as UK announced to relax rules and regulations for research on genetically engineered crops. Agriculture ministers in EU also agreed to relax rules on GMOs and the use of new precision techniques which can make the modification of a plant’s DNA at a faster pace and can result in strengthening the food sector in EU. According to the European Commission, the EU has spent €685.5 million on bioeconomy-oriented research related to NGTs, including €271 million for plant biotechnology research in the past decade. Companies can tap the market potential in Europe region and come up
If you have any questions, please feel free to contact our experts at:
The Report also Covers the Following Areas:
Genome Editing Market 2023-2030: Key Highlights
COVID-19 / Ukraine Crisis – Impact Analysis: Key Takeaways:
To Get a Customized Industry Analysis, Speak with our Research Analyst:
List of Key Market Players in Genome Editing Market:
The top 10 companies in this Industry are listed below:
Injectable Drug Delivery Market – The Injectable Drug Delivery market is Projected to Grow at a CAGR of 11.8% During the Forecast Period from 2023 to 2030. Increase in Number of Needle Injuries, Chronic Diseases and Worldwide Usage of Injections Increasing Its Growth Rate.
Lateral Flow Assays Market – Lateral Flow Assays Market size is Growing at a CAGR of 4.4% During the Forecast Period. It is Due to the Increasing Growth of Rapidly Increasing Population, High Infectious Disease Globally, Rising Demand for POC devices, Increasing use of Home-Based Assay Devices.
Oncology Drugs Market – The Oncology Drugs Market is Growing at a CAGR of 11.6% During the Forecast Period. It is Due to the Rise Increased Use of Tobacco, Advancement in Treatment Types and an Increasing Number of Cancer Cases.
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.
Mr. Venkat Reddy
USA: (+1) 518-282-4727